NephroGenex to price IPO of its common stock between $12.00 and $14.00

Company will sell stock through sole bookrunning manager Aegis Capital

By Devika Patel

Knoxville, Tenn., Dec. 23 - NephroGenex, Inc. will price its initial public offering of common stock with a 45-day greenshoe, according to a Form S-1 filed Monday with the Securities and Exchange Commission.

The stock will be sold at a price between $12.00 and $14.00 per share.

Aegis Capital Corp. is the sole bookrunning manager.

Proceeds will be used for clinical trials and development, general corporate purposes, general and administrative expenses, capital expenditures, working capital and prosecution and maintenance of intellectual property.

The Research Triangle Park, N.C., pharmaceutical company develops therapeutics to treat kidney disease. The company expects its shares will trade on the Nasdaq under the symbol "NRX."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.